ReviewEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs?
Review in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 28 citations in OpenAlex.
- Central vs. Peripheral Action of Thyroid Hormone in Adaptive Thermogenesis: A Burning Topic.Cells · 2021Review
- Thyroid hormones in diabetes, cancer, and aging.Aging cell · 2020Review
- Thyroid Dysfunction and Type 2 Diabetes Mellitus: Screening Strategies and Implications for Management.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Review
- Thyroid hormone: a resurgent treatment for an emergent concern.American journal of physiology. Lung cellular and molecular physiology · 2018Article
- Serum microRNA miR-206 is decreased in hyperthyroidism and mediates thyroid hormone regulation of lipid metabolism in HepG2 human hepatoblastoma cells.Molecular medicine reports · 2018Article
- Levothyroxine enhances glucose clearance and blunts the onset of experimental type 1 diabetes mellitus in mice.British journal of pharmacology · 2017Article
- Prediction of binding affinity and efficacy of thyroid hormone receptor ligands using QSAR and structure-based modeling methods.Toxicology and applied pharmacology · 2014Article
- Thyroid hormone regulation of metabolism.Physiological reviews · 2014Review
- New avenues for regulation of lipid metabolism by thyroid hormones and analogs.Frontiers in physiology · 2014Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo provide a comprehensive review of the discovery and development of selective thyroid hormone receptor agonists and provide a discussion of their use in hyperlipidemia, obesity, and type 2 diabetes mellitus.
methodsPreclinical and clinical English language literature from 1930 to present was reviewed and thematically summarized.
resultsHuman trials have shown that thyroid hormone receptor β (TRβ) agonists effectively lower low-density lipoprotein, triglycerides, apolipoprotein B, and lipoprotein(a) levels. In preclinical studies, TRβ agonists enhance reverse cholesterol transport and decrease atherosclerosis in selected models. While animal data suggest these drugs may have additional utility to modulate weight and improve glucose homeostasis, human studies have not shown similar results.
conclusionTRβ agonists are a novel therapeutic class for lipid management. Their mechanism of action for lipid lowering is distinct from statin drugs, suggesting a strong possibility for synergistic effects with combined therapy. The long-term effects of these drugs on cardiovascular outcomes, however, are unknown. Recently, the development of the most promising agent in this class, eprotirome, was halted over toxicology concerns following long-term canine studies. Consequently, the future of contemporary TRβ agonists is unclear. The creation of a next generation of TRβ agonists that provide additional tissue specific effects or bind TRβ with even higher selectivity may lead to improved safety and efficacy and allow for their application to other metabolic disorders like obesity and type 2 diabetes mellitus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.